Immunology of neuromyelitis optica: A T cell-B cell collaboration

Annals of the New York Academy of Sciences

Volumn 1283, Issue 1, 2013, Pages 57-66

  Mitsdoerffer, Meike ^a   Kuchroo, Vijay ^b   Korn, Thomas ^a,c  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Technische Universität München Munich Cluster for Systems Neurology   (Germany)

Author keywords

CNS; Inflammation; Neuromyelitis optica

Indexed keywords

CORTICOSTEROID; ECULIZUMAB; IMMUNOGLOBULIN G; RITUXIMAB; TOCILIZUMAB;

ARTICLE; AUTOIMMUNITY; B LYMPHOCYTE; CELL SPECIFICITY; CORTICOSTEROID THERAPY; HUMAN; IMMUNOLOGY; MYELOOPTIC NEUROPATHY; NONHUMAN; PATHOLOGY; PHENOTYPE; PLASMAPHERESIS; T LYMPHOCYTE;

EID: 84876792139     PISSN: 00778923     EISSN: 17496632     Source Type: Book Series    
DOI: 10.1111/nyas.12118     Document Type: Article

References (96)

1. Devic, E. 1894. Myélite subaiguë compliquée de névrite optique. Bull Med (Paris). 8: 1033-1034.
2. Wingerchuk, D.M. et al. 1999. The clinical course of neuromyelitis optica (Devic's syndrome). Neurology 53: 1107-1114.
3. Wingerchuk, D.M. et al. 2006. Revised diagnostic criteria for neuromyelitis optica. Neurology 66: 1485-1489.
4. Kitley, J. et al. 2012. Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135: 1834-1849.
5. Kobayashi, Z. et al. 2009. Intractable hiccup caused by medulla oblongata lesions: a study of an autopsy patient with possible neuromyelitis optica. J. Neurol. Sci. 285: 241-245.
6. Wingerchuk, D.M. et al. 2007. A secondary progressive clinical course is uncommon in neuromyelitis optica. Neurology 68: 603-605.
7. O'Riordan, J.I. et al. 1996. Clinical, CSF, and MRI findings in Devic's neuromyelitis optica. J. Neurol. Neurosurg. Psychiatry 60: 382-387.
8. Wingerchuk, D.M. et al. 2007. The spectrum of neuromyelitis optica. Lancet Neurol. 6: 805-815.
9. Lennon, V.A. et al. 2004. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364: 2106-2112.
10. Cloys, D.E. & M.G. Netsky . 1970. Neuromyelitis Optica. Amsterdam: North Holland Publishing Co.
11. Mandler, R.N. et al. 1993. Devic's neuromyelitis optica: a clinicopathological study of 8 patients. Ann Neurol. 34: 162-168.
12. Lucchinetti, C.F. et al. 2002. A role for humoral mechanisms in the pathogenesis of Devic's neuromyelitis optica. Brain 125: 1450-1461.
13. Prineas, J.W. & W.I. McDonald . 1997. Demyelinating diseases. In Graham, D. I. Lantos, P. L. (eds.): Greenfield's Neuropathology, 6th edition, Arnold, London, pp. 813-896.
14. Aboul-Enein, F. et al. 2003. Preferential loss of myelin-associated glycoprotein reflects hypoxia-like white matter damage in stroke and inflammatory brain diseases. J. Neuropathol. Exp. Neurol. 62: 25-33.
15. Lennon, V.A. et al. 2005. IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel. J. Exp. Med. 202: 473-477.
16. Misu, T. et al. 2007. Loss of aquaporin 4 in lesions of neuromyelitis optica: distinction from multiple sclerosis. Brain 130: 1224-1234.
17. Roemer, S.F. et al. 2007. Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis. Brain 130: 1194-1205.
18. Hinson, S.R. et al. 2008. Aquaporin-4-binding autoantibodies in patients with neuromyelitis optica impair glutamate transport by down-regulating EAAT2. J. Exp. Med. 205: 2473-2481.
19. Popescu, B.F. et al. 2011. Neuromyelitis optica unique area postrema lesions: nausea, vomiting, and pathogenic implications. Neurology 76: 1229-1237.
20. Lucchinetti, C.F. et al. 2011. Inflammatory cortical demyelination in early multiple sclerosis. N. Eng. J. Med. 365: 2188-2197.
21. Popescu, B.F. et al. 2010. Absence of cortical demyelination in neuromyelitis optica. Neurology 75: 2103-2109.
22. Nicchia, G.P. et al. 2004. The role of aquaporin-4 in the blood-brain barrier development and integrity: studies in animal and cell culture models. Neuroscience 129: 935-945.
23. Ma, T. et al. 1997. Generation and phenotype of a transgenic knockout mouse lacking the mercurial-insensitive water channel aquaporin-4. J. Clin. Invest. 100: 957-962.
24. Manley, G.T. et al. 2000. Aquaporin-4 deletion in mice reduces brain edema after acute water intoxication and ischemic stroke. Nat. Med. 6: 159-163.
25. Saadoun, S. et al. 2002. Aquaporin-4 expression is increased in oedematous human brain tumours. J. Neurol. Neurosurg. Psychiatry 72: 262-265.
26. Taniguchi, M. et al. 2000. Induction of aquaporin-4 water channel mRNA after focal cerebral ischemia in rat. Brain Res. Mol. Brain Res. 78: 131-137.
27. + channel protein Kir4.1 differs in low- and high-grade human brain tumors. Acta Neuropathol. 109: 418-426.
28. Waters, P. et al. 2008. Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol. 65: 913-919.
29. Hinson, S.R. et al. 2007. Pathogenic potential of IgG binding to water channel extracellular domain in neuromyelitis optica. Neurology 69: 2221-2231.
30. Jarius, S. et al. 2008. Mechanisms of disease: aquaporin-4 antibodies in neuromyelitis optica. Nat. Clin. Pract. Neurol. 4: 202-214.
31. Matiello, M. et al. 2007. Neuromyelitis optica. Curr. Opin. Neurol. 20: 255-260.
32. Watanabe, S. et al. 2007. Therapeutic efficacy of plasma exchange in NMO-IgG-positive patients with neuromyelitis optica. Mult. Scler. 13: 128-132.
33. Jarius, S. et al. 2008. Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain 131: 3072-3080.
34. Takahashi, T. et al. 2007. Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130: 1235-1243.
35. Weinstock-Guttman, B. et al. 2008. Neuromyelitis optica immunoglobulins as a marker of disease activity and response to therapy in patients with neuromyelitis optica. Mult. Scler. 14: 1061-1067.
36. Pittock, S.J. et al. 2006. Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch. Neurol. 63: 964-968.
37. Oshio, K. et al. 2004. Expression of aquaporin water channels in mouse spinal cord. Neuroscience 127: 685-693.
38. Saini, H. et al. 2010. Differential expression of aquaporin-4 isoforms localizes with neuromyelitis optica disease activity. J. Neuroimmunol. 221: 68-72.
39. Matsuoka, T. et al. 2007. Heterogeneity of aquaporin-4 autoimmunity and spinal cord lesions in multiple sclerosis in Japanese. Brain 130: 1206-1223.
40. Hinson, S.R. et al. 2012. Molecular outcomes of neuromyelitis optica (NMO)-IgG binding to aquaporin-4 in astrocytes. Proc. Natl. Acad. Sci. USA 109: 1245-1250.
41. Ratelade, J., J.L. Bennett & A.S. Verkman . 2011. Evidence against cellular internalization in vivo of NMO-IgG, aquaporin-4, and excitatory amino acid transporter 2 in neuromyelitis optica. J. Biol. Chem. 286: 45156-45164.
42. Kinoshita, M. et al. 2009. Astrocytic necrosis is induced by anti-aquaporin-4 antibody-positive serum. Neuroreport 20: 508-512.
43. Marignier, R. et al. 2010. Oligodendrocytes are damaged by neuromyelitis optica immunoglobulin G via astrocyte injury. Brain 133: 2578-2591.
44. Bradl, M. et al. 2009. Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann. Neurol. 66: 630-643.
45. Bennett, J.L. et al. 2009. Intrathecal pathogenic anti-aquaporin-4 antibodies in early neuromyelitis optica. Ann. Neurol. 66: 617-629.
46. Kinoshita, M. et al. 2009. Neuromyelitis optica: passive transfer to rats by human immunoglobulin. Biochem. Biophys. Res. Commun. 386: 623-627.
47. Saadoun, S. et al. 2010. Intra-cerebral injection of neuromyelitis optica immunoglobulin G and human complement produces neuromyelitis optica lesions in mice. Brain 133: 349-361.
48. Ratelade, J., J.L. Bennett & A.S. Verkman . 2011. Intravenous neuromyelitis optica autoantibody in mice targets aquaporin-4 in peripheral organs and area postrema. PLoS One 6: e27412.
49. Nicchia, G.P. et al. 2008. Expression of multiple AQP4 pools in the plasma membrane and their association with the dystrophin complex. J. Neurochem. 105: 2156-2165.
50. Zipfel, P.F. & C. Skerka . 2009. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 9: 729-740.
51. Nishiyama, S. et al. 2009. A case of NMO seropositive for aquaporin-4 antibody more than 10 years before onset. Neurology 72: 1960-1961.
52. Pittock, S.J. et al. 2008. Neuromyelitis optica and non organ-specific autoimmunity. Arch. Neurol. 65: 78-83.
53. Matsushita, T. et al. 2009. Association of the HLA-DPB1*0501 allele with anti-aquaporin-4 antibody positivity in Japanese patients with idiopathic central nervous system demyelinating disorders. Tissue Antigens 73: 171-176.
54. Leite, M.I. et al. 2012. Myasthenia gravis and neuromyelitis optica spectrum disorder: a multicenter study of 16 patients. Neurology 78: 1601-1607.
55. Pohl, M. et al. 2011. Pathogenic T cell responses against aquaporin 4. Acta Neuropathol. (Berl.) 122: 21-34.
56. Brum, D.G. et al. 2010. HLA-DRB association in neuromyelitis optica is different from that observed in multiple sclerosis. Mult. Scler. 16: 21-29.
57. Deschamps, R. et al. 2011. Different HLA class II (DRB1 and DQB1) alleles determine either susceptibility or resistance to NMO and multiple sclerosis among the French Afro-Caribbean population. Mult. Scler. 17: 24-31.
58. Varrin-Doyer, M. et al. 2012. Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann. Neurol. 72: 53-64.
59. Warabi, Y. et al. 2006. Characterization of the T cell receptor repertoire in the Japanese neuromyelitis optica: T cell activity is up-regulated compared to multiple sclerosis. J. Neurol. Sci. 249: 145-152.
60. Kalluri, S.R. et al. 2011. Functional characterization of aquaporin-4 specific T cells: towards a model for neuromyelitis optica. PLoS One 6: e16083.
61. Nelson, P.A. et al. 2010. Immunodominant T cell determinants of aquaporin-4, the autoantigen associated with neuromyelitis optica. PLoS One 5: e15050.
62. Mosmann, T.R. & R.L. Coffman . 1989. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu. Rev. Immunol. 7: 145-173.
63. Murphy, K.M. & S.L. Reiner . 2002. The lineage decisions of helper T cells. Nat. Rev. Immunol. 2: 933-944.
64. Korn, T. et al. 2009. IL-17 and Th17 cells. Annu. Rev. Immunol. 27: 485-517.
65. Korn, T., M. Mitsdoerffer & V.K. Kuchroo . 2010. Immunological basis for the development of tissue inflammation and organ-specific autoimmunity in animal models of multiple sclerosis. Results Probl. Cell Differ. 51: 43-74.
66. Sospedra, M. & R. Martin . 2005. Immunology of multiple sclerosis. Annu. Rev. Immunol. 23: 683-747.
67. Ishizu, T. et al. 2005. Intrathecal activation of the IL-17/IL-8 axis in opticospinal multiple sclerosis. Brain 128: 988-1002.
68. Uzawa, A. et al. 2009. Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J. Neurol. 256: 2082-2084.
69. Wang, H.H. et al. 2011. Interleukin-17-secreting T cells in neuromyelitis optica and multiple sclerosis during relapse. J. Clin. Neurosci. 18: 1313-1317.
70. Kira, J. 2011. Neuromyelitis optica and opticospinal multiple sclerosis: mechanisms and pathogenesis. Pathophysiology 18: 69-79.
71. Mitsdoerffer, M. et al. 2010. Proinflammatory T helper type 17 cells are effective B-cell helpers. Proc. Natl. Acad. Sci. USA 107: 14292-14297.
72. Wu, H.J. et al. 2010. Gut-residing segmented filamentous bacteria drive autoimmune arthritis via T helper 17 cells. Immunity 32: 815-827.
73. Peters, A. et al. 2011. Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity 35: 986-996.
74. Bettelli, E. et al. 2006. Myelin oligodendrocyte glycoprotein-specific T and B cells cooperate to induce a Devic-like disease in mice. J. Clin. Invest. 116: 2393-2402.
75. Krishnamoorthy, G. et al. 2006. Spontaneous opticospinal encephalomyelitis in a double-transgenic mouse model of autoimmune T cell/B cell cooperation. J. Clin. Invest. 116: 2385-2392.
76. Mealy, M.A. et al. 2012. Epidemiology of neuromyelitis optica in the United States: a multicenter analysis. Arch. Neurol. 69: 1176-1180.
77. Kitley, J. et al. 2012. Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79: 1273-1277.
78. Pollinger, B. et al. 2009. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J. Exp. Med. 206: 1303-1316.
79. Kalluri, S.R. et al. 2010. Quantification and functional characterization of antibodies to native aquaporin 4 in neuromyelitis optica. Arch. Neurol. 67: 1201-1208.
80. Keegan, M. et al. 2002. Plasma exchange for severe attacks of CNS demyelination: predictors of response. Neurology 58: 143-146.
81. Cree, B.A. et al. 2005. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 64: 1270-1272.
82. Jacob, A. et al. 2008. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch. Neurol. 65: 1443-1448.
83. Kim, S.H. et al. 2011. Repeated treatment with rituximab based on the assessment of peripheral circulating memory B cells in patients with relapsing neuromyelitis optica over 2 years. Arch. Neurol. 68: 1412-1420.
84. Bichuetti, D.B. et al. 2010. Neuromyelitis optica treatment: analysis of 36 patients. Arch. Neurol. 67: 1131-1136.
85. Jacob, A. et al. 2009. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch. Neurol. 66: 1128-1133.
86. Tradtrantip, L. et al. 2012. Anti-aquaporin-4 monoclonal antibody blocker therapy for neuromyelitis optica. Ann. Neurol. 71: 314-322.
87. Phuan, P.W. et al. 2012. A small-molecule screen yields idiotype-specific blockers of neuromyelitis optica immunoglobulin G binding to aquaporin-4. J. Biol. Chem. 287: 36837-36844.
88. Papeix, C. et al. 2007. Immunosuppressive therapy is more effective than interferon in neuromyelitis optica. Mult. Scler. 13: 256-259.
89. Uzawa, A. et al. 2010. Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis. Eur. J. Neurol. 17: 672-676.
90. Tanaka, M., K. Tanaka & M. Komori . 2009. Interferon-beta(1b) treatment in neuromyelitis optica. Eur. Neurol. 62: 167-170.
91. Kim, S.H. et al. 2012. Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder? Mult. Scler. 18: 1480-1483.
92. Min, J.H., B.J. Kim & K.H. Lee . 2012. Development of extensive brain lesions following fingolimod (FTY720) treatment in a patient with neuromyelitis optica spectrum disorder. Mult. Scler. 18: 113-115.
93. Kleiter, I. et al. 2012. Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch. Neurol. 69: 239-245.
94. Leonardi, C. et al. 2012. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N. Engl. J. Med. 366: 1190-1199.
95. Ayzenberg, I. et al. 2013. Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy. JAMA Neuro. 70: 394-397.
96. Kieseier, B.C. et al. 2012. Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses. Arch. Neurol. 1-4. DOI: 10.1001/jamaneurol.2013.668. [Epub ahead of print].